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Abstract
Background: Abnormal expression of Rho-GTPases has been reported in several human cancers. However, the
expression of these proteins in cervical cancer has been poorly investigated. In this study we analyzed the
expression of the GTPases Rac1, RhoA, Cdc42, and the Rho-GEFs, Tiam1 and beta-Pix, in cervical pre-malignant
lesions and cervical cancer cell lines.
Methods: Protein expression was analyzed by immunochemistry on 102 cervical paraffin-embedded biopsies:
20 without Squamous Intraepithelial Lesions (SIL), 51 Low- grade SIL, and 31 High-grade SIL; and in cervical cancer
cell lines C33A and SiHa, and non-tumorigenic HaCat cells. Nuclear localization of Rac1 in HaCat, C33A and SiHa
cells was assessed by cellular fractionation and Western blotting, in the presence or not of a chemical Rac1
inhibitor (NSC23766).
Results: Immunoreacivity for Rac1, RhoA, Tiam1 and beta-Pix was stronger in L-SIL and H-SIL, compared to
samples without SIL, and it was significantly associated with the histological diagnosis. Nuclear expression of Rac1
was observed in 52.9% L-SIL and 48.4% H-SIL, but not in samples without SIL. Rac1 was found in the nucleus of
C33A and SiHa cells but not in HaCat cells. Chemical inhibition of Rac1 resulted in reduced cell proliferation in
HaCat, C33A and SiHa cells.
Conclusion: Rac1 is expressed in the nucleus of epithelial cells in SILs and cervical cancer cell lines, and chemical
inhibition of Rac1 reduces cellular proliferation. Further studies are needed to better understand the role of Rho-
GTPases in cervical cancer progression.
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Background
Cervical cancer is the second most common malignant
neoplasia affecting woman worldwide. Infection with
High-Risk Human Papillomavirus (HR-HPV) is consid-
ered the main risk factor for developing cervical cancer
and its precursor lesions [1-3]. Development of cervical
Low-grade Squamous Intraepithelial Lesions (L- SIL) and
High-grade Squamous Intraepithelial Lesions (H-SIL),
and progression to invasive carcinoma, are associated
with alterations in the regulation of several cellular
processes such as cell cycle progression, apoptosis, and
DNA repair [2,4,5]. The HR-HPV oncoproteins E6 and
E7 are responsible for many of these alterations, they act
by binding to, and/or modifying the expression/activity
of a growing number of cellular proteins [6], includ-
ing p53 [7], pRb [8], p21 [9,10], and p27 [11,12]. Rho-
GTPases are small signaling proteins involved in the
regulation of crucial cellular functions such as cell shape,
cell-cell adhesion, cell proliferation, cell division, migra-
tion and invasion [13-15]. Experiments using cell culture
and animal models have demonstrated an important role
for these proteins in carcinogenesis [16,17]. Moreover, it
has been shown that expression of some Rho-GTPases
and their regulatory proteins is altered in human cancers
such as prostate, colon, lung, and breast cancer [18].
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Cell culture experiments showed that RhoC regulates
invasion and motility of cervical cancer cells [19,20].
Furthermore, it has been reported that RhoC is overex-
pressed in biopsies from squamous carcinoma of the cer-
vix (SCC) and cervical intraepithelial neoplasia (CIN) II/
III when compared to normal cervical epithelium and
CIN I [21]. However, expression of other Rho-GTPases
has not been investigated in cervical cancer or its precur-
sor lesions. The aim of this study was to investigate the
alterations on the expression of the GTPases Rac1,
RhoA, and Cdc42, and the Rho GEFs Tiam1 and beta-Pix
in cervical premalignant lesions.
Materials and methods
Sample selection
102 paraffin-embedded cervical tissue specimens were
obtained from the Department of Pathology at the “Vice-
nte Guerrero” General Regional Hospital (IMSS), in Aca-
pulco, Mexico. Eighty-two samples corresponded to
cervical biopsies or cones with confirmed histological diag-
nosis of L-SIL (n = 51) or H-SIL (n = 31), and 20 corre-
sponded to cervical tissue specimens without SIL, selected
from patients undergoing hysterectomy for benign condi-
tions, without a history of SIL or abnormal Pap results.
One pathologist (LSL) reviewed all of the slides to confirm
the diagnoses. All SIL cases were additionally reviewed by
a second pathologist (JFC) to establish a consensus diag-
nosis (discrepancies relative to the original diagnoses were
resolved by the interpretation of a third pathologist).
Approval to conduct this study was obtained from the
Institutional Ethics Comitee at the “Universidad Autón-
oma de Guerrero”. The study was conducted in compli-
ance with the Helsinki Declaration.
Detection of HR-HPV
The presence of HR-HPV was determined by in situ
hybridization using the GenPoint tyramide amplification
signal kit (DAKO, Carpinteria, CA). Briefly, 3- micron
paraffin sections were placed on silanized slides, deparaf-
finized, and incubated for 5 min at 37°C with proteinase
K. Samples were dehydrated, and a mixture containing a
pool of biotinilated DNA probes (directed against HPV
16, 18, 31, 33, 39, 45, 51, 52, 56, 58, 59 and 68 types) was
added to each section. Sections were covered with a glass
coverslip, denatured for 10 min at 95°C, and hybridiza-
tion was performed for 20 h at 37°C in a humidified
atmosphere in a Dako hybridizer (Dako, Carpinteria,
CA). The slides were incubated with a streptavidin perox-
idase-conjugated primary antibody, followed by incuba-
tion with biotil-tyramide, and with streptavidin. The
reaction was developed by adding DAB, followed by
staining with Mayer’s hematoxylin (Merck, Germany),
and mounted with Entellan mounting medium (Merck,
Germany). The positive reaction was seen as a maroon or
brown nuclear signal (Additional file 1: Figure S1).
Immunohistochemistry and immunocytochemistry
For immunohistochemistry, 3-micron paraffin sections
were deparaffinized and rehydrated, followed by 20 min
incubation in sodium citrate buffer (pH 6.0) at 110°C for
antigen retrieval, using a pressure cooker (T-FAL Clipso).
Samples were incubated for 10 min with immunodetector
peroxidase block solution (Bio-SB Inc. Santa Barbara, CA.)
to inactivate endogenous peroxidase, blocked with PBS +
1% BSA during 30 min, and incubated with primary anti-
bodies for 1 h at room temperature. For immunocyto-
chemistry, 5 × 104 HaCat, C33A, or SiHa cells were plated
on glass coverslips in 6-well culture plates. Cells were
maintained on DMEM medium (Invitrogen, Carlsbad,
CA,) supplemented with 10% FBS (Byproductos, Mexico)
at 37°C in a 5% CO2 atmosphere. Where indicated, cells
were treated with the Rac1 chemical inhibitor NSC23766
(Santa Cruz Biotechnology Inc, CA) at 25 μM or 50 μM.
24 h or 48 h after plating, cells were fixed with methanol-
acetone (1:1) for 30 min, washed with PBS and antigen
retrieval, blocking and primary antibody incubation were
performed as described for immunohistochemistry. Pri-
mary antibodies were detected using a Mouse/Rabbit
Immunodetector HRPw/DAB kit (Bio-SB Inc. Santa Bar-
bara, CA.), following manufacturer’s instructions, samples
were counterstained with Harris’s hematoxylin and
mounted using Entellan mounting medium (Merck, North
America Inc). Antibodies used were: Rac1 (C-14), RhoA
(C-15), Cdc42 (B-8), Tiam1 (C-16), and beta- Pix (C-19)
(Santa Cruz Biotechnology Inc, CA). The intensity of cyto-
plasmic staining was scored as weak, moderate or strong
at 40× magnification (Additional file 2: Figure S2).
Cellular fractionation and western blotting
Cells were seeded on petri dishes and incubated for 24 h
in the presence or absence of the Rac1 inhibitor
NSC23766. Cells were washed with PBS and lysed in
500 μl of buffer A (10 mM HEPES, pH 9.7; 10 mM KCl,
0.1 M EDTA, 1 mM DTT; 0.5 mM PMSF plus protease
inhibitors) directly on the plate and the protein lysate
was transferred to a new microtube and centrifuged at
15 000 g for 3 min at 4°C. The cytoplasmic fraction
(supernatant) was recovered in a new microtube and the
pellet was resuspended in 150 μl of RIPA buffer (150
mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate,
0.1% SDS, 50 mM Tris pH8). The supernatant (nuclear
fraction) was transferred to a new microtube. For total
protein extracts, cells were lysed with RIPA buffer (50
mM Tris-HCl pH 7.6, 160 mM NaCl, 0.5 mM EDTA/
EGTA, 1% Triton X-100, 10% glycerol, 1 mM PMSF
and 1 μg/ml leupeptin). Whole cell, cytoplasmic and
nuclear proteins were separated by SDS- PAGE in 10%
acrylamide gels, transferred to PVDF membranes and
detected by Western blot using antibodies against alpha-
tubulin, lamin B, Rac1 (all from Millipore) and Tiam1
(Santa Cruz Biotechnology).
Mendoza-Catalán et al. BMC Cancer 2012, 12:116
http://www.biomedcentral.com/1471-2407/12/116
Page 2 of 9
Cell proliferation assay
8 × 103 cells were plated on 24-well plates (Sarstedt AG
& CO, Germany) and cultured in DMEM medium sup-
plemented with 10% FBS for 24 h. Cells were treated
with the Rac1 inhibitor NSC23766 (Santa Cruz Biotech-
nology Inc, CA) at 25 μM or 50 μM or with vehicle.
Cells were fixed after 48 h of treatment, in 4% formalde-
hyde for 30 min. Cell proliferation was determined using
crystal violet assay. The relative number of cells was
determined by measuring the optical density of each
well at 600 nm in a biophotometer (Eppendorf RS-2312
DH 8.5 mm).
Statistical analysis
Association between variables was evaluated by Chi
squared test or Fisher’s exact test, as appropriate. Differ-
ences between data were determinate by two-way
ANOVA test. A result was considered to be statistically
significant when the p value was < 0.05. Statistical analy-
sis was performed using the software STATA v9.2 or
GraphPad Prism v5.03.
Results
Overexpression of rho-GTPases and RhoGEFs in cervical
pre-malignant lesions
We first determined HR-HPV infection as described under
materials and methods. 20 samples were negative and 62
were positive for HR-HPV. In 20 samples HR-HPV infec-
tion could not be determined (Additional file 3: Table S1).
Next, we determined the expression of Rac1, RhoA,
Cdc42, Tiam1 and beta -Pix in cervical samples. Expres-
sion of the five proteins was observed in all cervical sam-
ples and the intensity of the signal for Rac1, RhoA, Tiam1,
and beta-Pix was stronger in L-SIL and H-SIL, when com-
pared to samples without SIL (Figure 1). As shown in
Table 1, in the majority of samples without SIL the immu-
noreactivity for the five proteins was weak, only 35% and
20% of these samples had moderate/strong signal for Rac1
and Tiam1, respectively. In contrast, 64.7% L-SIL and
74.2% H-SIL showed moderate/strong signal for Rac1, and
80.4% L-SIL and 80.6% H-SIL had moderate/strong reac-
tivity for Tiam1. Similarly, moderate/strong reactivity of
RhoA was observed in 40%, 51%, and 71% for samples
without SIL, L-SIL and H-SIL, respectively. Cdc42 reactiv-
ity was moderate/strong in 40% of samples without SIL,
41.2% L-SIL, and 61.3% H-SIL. For beta-Pix, moderate/
strong reactivity was observed in 25% of samples without
SIL, 37.2% L-SIL, and 64.5% H-SIL (Table 1). A significant
association was found between the immunoreactivity of
Rac1 and L-SIL (p = 0.02) and H-SIL (p = 0.005); RhoA
and H-SIL (p = 0.03); Tiam1 and L-SIL (p < 0.001) and H-
SIL (p < 0.001); and beta-Pix and H-SIL (p = 0.006). No
significant association was found between the reactivity of
Cdc42 and L-SIL or H-SIL, or between the reactivity of
RhoA or beta-Pix and L-SIL. We found that the intensity
of Tiam1 immunoreactivity was associated with HR-HPV
infection (p = 0.014), whereas no significant association
was found between the immunoreactivity of Rac1, Cdc42,
RhoA or beta-Pix, and HR-HPV infection (data not
shown).
Nuclear expression of Rac1 in SILs and cervical cancer
derived cell lines
We observed a strong nuclear reactivity for Rac1 in a sub-
set of L-SIL and H-SIL samples, whereas no nuclear reac-
tivity was observed in samples without SIL (Figure 2A).
Nuclear staining was observed along all layers of the
epithelium and was found in 52.9% L-SIL and 48.4% H-SIL
(Table 2). In line with these observations, nuclear immu-
noreactivity for Rac1 was observed in cervical cancer
derived cell lines C33A (HPV-negative) and SiHa (HPV-
16), but not in immortalized non-tumorigenic keratino-
cytes (HaCat). A strong perinuclear Rac1 immunoreactivity
was also observed in SiHa cells (Figure 2B). These observa-
tions were further confirmed using cellular fractionation
and Western blot analyses. As shown in Figure 2D, Rac1
was detected in the cytoplasmic fraction of the three cell
lines, and in the nuclear fraction of C33A and SiHa cells,
but not in the nuclear fraction of Hacat cells (Figure 2C).
Using Western blot analysis on whole-cell extracts from
HaCat, C33A and SiHa cells, we found that Rac1 protein
levels are similar in all cell lines (Figure 2D).
Chemical inactivation of Rac1 reduces its nuclear
immunoreactivity and inhibits cell proliferation
To test whether nuclear Rac1 expression in C33A and
SiHa cells is dependent on its activation status, C33A and
SiHa cells were treated with 25 μM or 50 μM of the Rac1
inhibitor NSC23766. Imnunocytochemical analyses of
NSC23766-treated cells showed an apparent reduction in
the nuclear Rac1 immunoreactivity in both cell lines, as
well as a reduction of the perinuclear immunoreactivity
in SiHa cells (Figure 3A). However, cellular fractionation
and Western blot analysis demonstrated that treatment
with the Rac1 inhibitor does not affect the nuclear locali-
zacion of Rac1 in these cell lines (Figure 3B). We next
tested whether the chemical inhibition of Rac1 has an
effect on the proliferation of Hacat, C33A and SiHa cells.
We found that tNSC23766 treatment resulted in a signif-
icant decrease in the proliferation of the three cell lines
(Figure 3C).
Discussion
Overexpression of Rho-GTPases and Rho-GEFs has been
described in various types of human tumors [18], and in
some cases overexpression is associated with tumor pro-
gression or poor prognosis [22,23]. However, little is known
about the role of Rho-GTPases in cervical carcinogenesis.
Mendoza-Catalán et al. BMC Cancer 2012, 12:116
http://www.biomedcentral.com/1471-2407/12/116
Page 3 of 9
Here, using immunohistochemistry, we show that the
immunoreactivity of the GTPases Rac1 and RhoA, and the
Rho GEFs Tiam1 and beta-Pix, is increased in SILs, com-
pared to cervical epithelium without SIL. Interestingly, we
found that Rac1 is present in the nucleus of a subset of L-
SIL and H-SIL, but not in samples without SIL. In agree-
ment with these findings, we observed nuclear localization
of Rac1 in cancer derived C33A and SiHa cells but not in
non-tumorigenic HaCat cells.
Rac1 has a nuclear localization signal (NLS) [24], and it
has been recently shown that the importin Karyopherin
alpha 2 (KPNA2) mediates Rac1 nuclear import trough
the interaction with its NLS, and that KPNA2-mediated
nuclear import of Rac1 requires Rac1 activation [25].
Here we show that the nuclear localization of Rac1 in
C33A and SiHa cells is not affected by treatment with
the Rac1 inhibitor NSC23766. These data indicate that in
these cells, the presence of Rac1 in the nucleus is not
dependent on its activation. Michaelson et al. (2010)
showed that Rac1 translocates to the nucleus during the
G2 phase of the cell cycle, and that targeting an active
form of Rac1 to the nucleus promotes cell proliferation
[26]. We found that chemical inhibition of Rac1 reduces
the proliferation of cervical cancer cell lines C33A and
SiHa, as well as that of non-tumorigenic HaCat cells. In
HaCat cells, in which Rac1 is localized to the cytoplasm,
chemical inhibition of Rac1 may reduce its nuclear trans-
location during the G2 phase of the cell cycle, resulting
Figure 1 Expression of Rho-GTPases and Rho-GEFs in cervical epithelium without squamous intraepithelial lesions, low-grade
squamous intraepithelial lesions (L-SIL), and high-grade squamous intraepithelial lesions (H-SIL). Representative images of
immunohistochemical analysis of Rac1, RhoA, Cdc42, Tiam, and beta-Pix expression. Magnification: 40 ×.
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in a reduction in cell proliferation. Buongiorno et al.
(2008) showed that an inactive form of Rac1 is present in
the nucleus of colorectal cancer cells, where it associates
with the transcription factor TCF-4 [27]. Interestingly,
these authors demonstrated that activation of the Wnt
signaling pathway induced the nuclear translocation of
Tiam1, a Rac1-specific activator, in a complex with beta-
catenin, and that once in the nucleus a beta-catenin/
Tiam1/TCF4/Rac1 complex can be formed, resulting in
the activation of Rac1 and transcriptional activation of
Wnt target genes [27]. Activation of the Wnt signaling
pathway plays an important role during cervical cancer
progression [28,29]; therefore nuclear Rac1 may coop-
erate with this pathway to stimulate proliferation of cer-
vical cancer cells. We found that chemical inhibition
Rac1 in C33A and SiHa cells, in which Rac1 localizes
both to the cytoplasm and the nucleus, impairs prolifera-
tion without affecting Rac1 nuclear localization. In these
cells, inactivation of the nuclear pool of Rac1 may impair
the interaction of Rac1 with nuclear proteins such as
TCF4 and beta-catenin, resulting in a reduction in the
expression of proliferation-related genes and therefore
the reduction in cell proliferation. However, Rac1 can
also regulate proliferation trough the activation of cyto-
plasmic signaling pathways such as NF-kB [30], MAPK
[31], Jak/Stat [32] and Wnt [33] pathways. Therefore, it is
possible that inhibition of the cytoplasmic pool of Rac1
in both cervical cancer-derived and non-tumorigenic
cells may result in a reduction of cell proliferation, inde-
pendently of Rac1 nuclear functions. Altogether, these
data suggest that nuclear Rac1 may play an important
role in regulating cell proliferation and gene expression
in cervical cells, and that the presence of Rac1 in the
nucleus of cervical epithelial cells from pre-malignant
lesions may contribute to cancer progression.
In our study, we observed overexpression of Rac1,
RhoA and Tiam1 in L-SIL and H-SIL, and beta-Pix in H-
SIL, when compared with epithelia without SIL. In vitro
experiments in HeLa cells demonstrate that Rac1 [34]
and Rho [35] activation is required for cell growth and
migration. Similarly, experiments in CaSki cells showed
that inhibition of migration and invasion by the antican-
cer agent JOTO1007, is associated with a reduction in
the expression of RhoA and the Rho downstream effector
ROCK-1 [36]. Moreover, experimental evidences indicate
that Rho GTPases play a role in cellular transformation.
It has been shown that Rac1 and its activator Tiam1 are
required for Src-induced transformation [37]. Similarly, it
has been demonstrated that Rac1 and Cdc42 are neces-
sary for H-Ras-induced transformation, although overex-
pression of constitutively active forms of Rac1 or Cdc42
is not sufficient for cellular transformation [38]. It has
also been shown that RhoA overexpression can induce
pre-neoplastic transformation of primary mammary
epithelial cells [39]. These data suggest that overexpres-
sion of Rho GTPases in SILs may cooperate with other
signaling pathways to promote tumor progression.
We found that the increased immunoreactivity of Rac1,
RhoA and beta-Pix correlates with the histological diag-
nosis but not with HR-HPV infection. In contrast, Tiam1
immunoreactivity was associated with both histological
diagnosis and HR-HPV infection. These observations
suggest that altered expression of Tiam1, but not that of
Rac1, RhoA and beta-Pix may be dependent of HR-HPV
infection. However, further studies are needed in order
to determine if increase levels of Rho proteins and their
GEFs is induced directly by HPV oncoproteins or is the
result of a secondary event related to the progression of
the malignancy. Our data indicate that nuclear expres-
sion of Rac1 in cervical lesions may be independent of
HR-HPV infection as not all HR-HPV positive samples
have nuclear staining for Rac1. Moreover, both HPV-
negative and HPV-positive cervical cancer derived cells
have nuclear staining for Rac1. However, as mentioned
above, it is possible that infection with other HPV types
not detected by ISH technique we used in this work may
affect the subcellular localization of Rac1. Moreover, ISH
does not allow us to identify which HR-HPV type is pre-
sent in the samples, and it is possible that infection with
some HR-HPVs such as HVP16 and HPV18 will have a
more dramatic effect on the expression of these proteins.
Table 1 Association between the intensity of Rac1, RhoA,












Low 65 (13) 35.3 (18) 0.02 25.8 (8) 0.005
moderate/high 35 (7) 64.7 (33) 74.2 (23)
Cdc42
Low 60 (12) 58.8 (30) 0.93 38.7 (12) 0.12
moderate/high 40 (8) 41.2 (21) 61.3 (19)
RhoA
Low 60 (12) 49 (25) 0.41 29 (9) 0.03
moderate/high 40 (8) 51(26) 71(22)
Tiam1
Low 80 (16) 19.6 (10) < 0.001 19.4 (6) < 0.001
moderate/high 20 (4) 80.4 (41) 80.6 (25)
Beta-Pix
Low 75 (15 62.8 (32) 0.33 35.5 (11) 0.006
moderate/high 25 (5) 37.2 (19) 64.5 (20)
Total 20 51 31
*IR = immunoreactivity; † = Chi squared test
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This could be of particular relevance for our study popu-
lation, as in a recent study performed on women from
Guerrero state in the south of Mexico, Illades-Aguiar et
al., (2010) reported that whereas HPV16 is the most fre-
quent HPV type present in women with cervical cancer,
the most frequent type in women with L-SIL was HPV33
[40]. We also found moderate-strong reactivity for the
five proteins in samples without SIL (Table 1). Recent
evidences demonstrate infection with HR-HPVs in
patients without SILs [40-42]. It is possible that some of
the samples without SIL that showed moderate-strong
reactivity are positive to HR-HPV. As mentioned above,
we used ISH for the detection of HR-HPV infection.
However this method has limitations as it detects only a
subset of HR-HPV types. Further studies using more sen-
sitive techniques such as PCR-RFLP or sequencing for
the detection and typing of HPV infection will be
required to answer to this concern. Finally, we could not
determine HR-HPV infection in a subset of samples.
Further investigation is required to determine the possi-
ble association between the overexpression of Rho-
GTPases and HR-HPV infection.
One of the limitations in our study is that expression
of the analyzed proteins in cervical biopsies was studied
only by immunochemistry. Further studies using Wes-
tern blotting, as well as analysis of a larger number of
samples are required.
Conclusions
In conclusion, Rac1 and Tiam1 are overexpressed in L-
SIL and H-SIL, RhoA and beta-Pix are overexpressed in
Figure 2 Nuclear expression of Rac1 in squamous intraepithelial lesions and cervical cancer cell lines. A. Representative images showing
nuclear Rac1 expression in low-grade squamous intraepithelial lesions (L-SIL) and high-grade squamous intraepithelial lesions (H-SIL) but not in
epithelium without squamous SIL. B. Representative images of immunocytochemical analysis showing nuclear Rac1 expression in cervical cancer
cells C33A and SiHa, but not in non-tumorigenic Hacat cells. Magnification: 40×. C. Western blot analysis of Rac1 protein levels in cytoplasmic (C)
and nuclear (N) protein extracts from HaCat, C33A and SiHa cells. D. Western blot analysis of Rac1 and Tiam1 protein levels in whole-cell extracts
from HaCat, C33A and SiHa cells.
Table 2 Association between the Rac1 nuclear
immunoreactivity, and the histopathological diagnosis
Histopathological diagnosis







Negative 100 (20) 47.1 (24) 51.6 (16)
Positive 0 (0) 52.9 (27) 48.4 (15) < 0.001
Total 20 51 31
* = Fisher’s exact test: without SIL versus L-SIL, and without SIL versus H-SIL.
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Figure 3 Effect of the Rac1 chemical inhibitor NSC23677 on the subcellular localization of Rac1, and on cell proliferation. A.
Representative images of immunocytochemical analysis for Rac1 in C33A and SiHa cells, treated or not with the Rac1 inhibitor NSC23677. B.
Detection of Rac1 in cytoplasmic (C) and nuclear (N) proteins from HaCat, C33A and SiHa cells treated or not with the Rac1 inhibitor NSC23677.
Lamin B was used as a nuclear marker and a-tubilin is a cytoplasmic marker. C. Results from crystal violet cell proliferation assays on HaCat, C33A
and SiHa cells treated or not with the Rac1 inhibitor NSC23766 for 48 h. Data shown are average optical density values plus standard deviation
of experiments performed in triplicate.
Mendoza-Catalán et al. BMC Cancer 2012, 12:116
http://www.biomedcentral.com/1471-2407/12/116
Page 7 of 9
H-SIL. Rac1 is expressed in the nucleus of cervical pre-
malignant-lesions and cervical cancer derived cells lines.
The chemical inhibition of Rac1 inhibits cell prolifera-
tion in Hacat, C33A and SiHa cells. To our knowledge,
this is the first report showing abnormal expression of
Rho-GTPases in cervical cancer, Further studies are
needed to better understand the role of the overexpres-
sion of Rho-GTPases, as well as the nuclear Rac1
expression in cancer progression.
Additional material
Additional file 1: Figure S1. HR-HPV detection by ISH. Representative
images of (a) L-SIL sample in which HPV-probe set was excluded
(negative control); (b-d) HR-HPV positive H-SIL showing strong nuclear
staining. (a-c) 40×, (d) 100 ×.
Additional file 2: Figure S2. Establishment of the criteria for
interpretation of IHC results. To analyze the differences in the intensity in
immunoreactivity of the five proteins, we defined four categories based
on signal intensity: a) negative, b) low, c) moderate and d) strong.
Additional file 3: Table S1. Characteristics of the study population.
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